Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Virios Therapeutics stock | $5.09
Learn how to easily invest in Virios Therapeutics stock.
Virios Therapeutics, Inc is a biotechnology business based in the US. Virios Therapeutics shares (VIRI) are listed on the NASDAQ and all prices are listed in US Dollars. Virios Therapeutics employs 3 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Virios Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – VIRI – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Virios Therapeutics stock price (NASDAQ: VIRI)Use our graph to track the performance of VIRI stocks over time.
Virios Therapeutics shares at a glance
|Latest market close||$5.09|
|52-week range||$4.60 - $16.71|
|50-day moving average||$6.14|
|200-day moving average||$6.20|
|Wall St. target price||$18.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
Buy Virios Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Virios Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Virios Therapeutics price performance over time
|1 week (2021-07-21)||N/A|
|1 month (2021-07-01)||-19.72%|
|3 months (2021-04-30)||-5.91%|
|6 months (2021-01-28)||N/A|
|1 year (2020-07-28)||N/A|
|2 years (2019-07-28)||N/A|
|3 years (2018-07-28)||N/A|
|5 years (2016-07-28)||N/A|
Virios Therapeutics financials
|Gross profit TTM||$0|
|Return on assets TTM||-39.34%|
|Return on equity TTM||-116.73%|
|Market capitalisation||$48.1 million|
TTM: trailing 12 months
Shorting Virios Therapeutics shares
There are currently 75,958 Virios Therapeutics shares held short by investors – that's known as Virios Therapeutics's "short interest". This figure is 7.1% down from 81,732 last month.
There are a few different ways that this level of interest in shorting Virios Therapeutics shares can be evaluated.
Virios Therapeutics's "short interest ratio" (SIR)
Virios Therapeutics's "short interest ratio" (SIR) is the quantity of Virios Therapeutics shares currently shorted divided by the average quantity of Virios Therapeutics shares traded daily (recently around 165126.08695652). Virios Therapeutics's SIR currently stands at 0.46. In other words for every 100,000 Virios Therapeutics shares traded daily on the market, roughly 460 shares are currently held short.
To gain some more context, you can compare Virios Therapeutics's short interest ratio against those of similar companies.
However Virios Therapeutics's short interest can also be evaluated against the total number of Virios Therapeutics shares, or, against the total number of tradable Virios Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Virios Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Virios Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0112% of the tradable shares (for every 100,000 tradable Virios Therapeutics shares, roughly 11 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Virios Therapeutics.
Find out more about how you can short Virios Therapeutics stock.
Virios Therapeutics share dividends
We're not expecting Virios Therapeutics to pay a dividend over the next 12 months.
You may also wish to consider:
- Gilead Sciences (GILD.US) (3.93% forward annual dividend yield)
Virios Therapeutics overview
Virios Therapeutics, Inc. , a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. Its lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was incorporated in 2012 and is headquartered in Alpharetta, Georgia.
Stocks similar to Virios Therapeutics
Virios Therapeutics in the news
new option listings on July 28th
Virios Therapeutics Highlights Clinical Sites Fully Operational in Phase 2b Fibromyalgia Study Featuring FDA "Fast Track" Review Designated Antiviral Therapy, Oral IMC-1
Virios Therapeutics announces all 41 sites in FM trial enrolling patients
Frequently asked questionsWhat percentage of Virios Therapeutics is owned by insiders or institutions?
Currently 10.692% of Virios Therapeutics shares are held by insiders and 12.289% by institutions. How many people work for Virios Therapeutics?
Latest data suggests 3 work at Virios Therapeutics. When does the fiscal year end for Virios Therapeutics?
Virios Therapeutics's fiscal year ends in December. Where is Virios Therapeutics based?
Virios Therapeutics's address is: 44 Milton Avenue, Alpharetta, GA, United States, 30009
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert